Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 4, Issue 7, Pages 965-972Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.4.7.965
Keywords
efavirenz; treatment naive; novel antiretroviral agents
Funding
- NIAID NIH HHS [K23 AI066901] Funding Source: Medline
Ask authors/readers for more resources
Background: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available. Objective: This article will review relevant efficacy and safety data of efavirenz compared to these novel agents or certain common alternate drugs currently used as initial therapy in treatment-naive patients. Methods: Published articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents were evaluated. Results/conclusions: Efavirenz will continue to be preferred initial therapy for now. if longer-term studies of integrase inhibitors and second-generation NNRTIs confirm initial findings, they will eventually supplant efavirenz as preferred first-line agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available